Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

AKESO Aktie

 >AKESO Aktienkurs 
9.544 EUR    -3.1%    (TradegateBSX)
Ask: 9.594 EUR / 417 Stück
Bid: 9.446 EUR / 424 Stück
Tagesumsatz: 145 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
AKESO Aktie über LYNX handeln
>AKESO Performance
1 Woche: -2,7%
1 Monat: -19,2%
3 Monate: -14,8%
6 Monate: -31,7%
1 Jahr: -29,8%
laufendes Jahr: -19,8%
>AKESO Aktie
Name:  AKESO INC. O.N.
Land:  China
Sektor:  Gesundheit
ISIN/ Wkn:  KYG0146B1032 / A2P200
Symbol/ Ticker:  4RY (Frankfurt)
Kürzel:  FRA:4RY, ETR:4RY, 4RY:GR
Index:  -
Profil:  Akeso Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative, therapeutic solutions for the treatment of various diseases, particularly relating to oncology and autoimmune disorders. As a key pla..
>Volltext..
Marktkapitalisierung:  8954.94 Mio. EUR
Unternehmenswert:  8398.63 Mio. EUR
Umsatz:  446.3 Mio. EUR
EBITDA:  -71.13 Mio. EUR
Nettogewinn:  -124.67 Mio. EUR
Gewinn je Aktie:  -0.14 EUR
Schulden:  666.25 Mio. EUR
Liquide Mittel:  145.7 Mio. EUR
Operativer Cashflow:  -80.4 Mio. EUR
Bargeldquote:  3.2
Umsatzwachstum:  47.09%
Gewinnwachstum:  -22.08%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  AKESO
Letzte Datenerhebung:  15.11.26
>AKESO Kennzahlen
Aktien/ Unternehmen:
Aktien: 938.59 Mio. St.
Frei handelbar: 77.86%
Leerverk. Aktien: -
Rückkaufquote: -4.34%
Mitarbeiter: 3761
Umsatz/Mitarb.: 0.1 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 73.46%
Bewertung:
KGV: -
KGV lG: -
KUV: 21.06
KBV: 8.45
PEG-Ratio: -4.75
EV/EBITDA: -
Rentabilität:
Bruttomarge: 75.9%
Gewinnmarge: -27.93%
Operative Marge: -24.68%
Managementeffizenz:
Gesamtkaprendite: -6.47%
Eigenkaprendite: -12.79%
>AKESO Peer Group
Gesundheit, Antikörper- Behandlung, Autoimmunerkrankungen, Onkologie/ Krebs- Behandlung
 
16.11.26 - 03:15
AKESO Plunges as Much as 32% Amid Forced Selling as Ivonescimab Fails to Obtain FDA Approval for US Launch (AAStocks)
 
AKESO (09926.HK) shares once plunged 32% this morning (16th), hitting a low of HKD56.1. The stock was last reported at HKD60.6, down 26.37%, with trading volume surging to 28.1376 million shares, involving HKD1.724 billion in turnover.AKESO's overseas partner Summit Therapeutics Inc. (SMMT.US) announced that it had received a Co......
16.11.26 - 03:00
H Shrs: HSI Opens Up 71 pts; NEW WORLD DEV Resumes Trading, Plunges 45.5%; AKESO Opens Down 15%; JD-SW, BIDU-W Each Open Over 2% Higher (AAStocks)
 
US stocks showed mixed performance last Friday (13th). The DJIA fluctuated before closing up 50 pts, while the S&P 500 fell 0.4%. The Nasdaq closed down 0.9%, with NVIDIA Corporation (NVDA.US) opening higher but closing 2% lower. This morning (16th), the HSI opened at 23,708, up 71 pts or 0.3%; the HSCEI opened at 7,965, up 27 p......
06.11.26 - 03:39
Phase II Study of Ivonescimab in the Perioperative Setting for Resectable NSCLC Published in Nature Medicine (PR Newswire)
 
HONG KONG, Nov. 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that results from a Phase II clinical study evaluating its first-in-class PD-1/VEGF bispecific antibody ivonescimab in the perioperative treatment of resectable non-small cell lung cancer (NSCLC) have been......
05.11.26 - 05:24
Ivonescimab Receives NMPA Priority Review for First-Line Biliary Tract Cancer (PR Newswire)
 
HONG KONG, Nov. 4, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced that ivonescimab in combination with chemotherapy for the first-line treatment of locally advanced or metastatic biliary tract cancer (BTC) has been granted Priority Review by China's National Medical......
04.11.26 - 22:42
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026 (Business Wire)
 
Recent $2 Billion Strategic Equity Investment in Summit by AstraZeneca and Summit's Expanding Network of Clinical Collaborations Underscore Confidence in Ivonescimab's Potential Ivonescimab Global Clinical Development Program Continues to Grow with New Studies in Bladder and Kidney Cancers Ivonescimab Regimens Demonstrate Statistically Significant Overall Survival Benefits Versus Pembrolizumab in PD-L1–Positive Advanced NSCLC and Versus Durvalumab Plus Chemotherapy in Biliary Tract Cancer in Akeso's Phase III Studies Conducted in China Summit Closes Third Quarter with $629.8 Million in Cash and Investments and Received $2.0 Billion from AstraZeneca in Connection with an Equity Investment Post Third QuarterMIAMI--(BUSINESS WIRE)--$SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the third quarter and nine months ended September 30, 2026, and provided an update on clinical and operational progress. “This quarter marked a period of meaningful momentum for Summit, ...
26.10.26 - 05:15
AKESO Releases Phase III Study Results of Ivonescimab Combination Therapy for Advanced Biliary Tract Cancer (AAStocks)
 
AKESO (09926.HK) announced that the results of the HARMONi-GI1/AK112-309 study were recently presented at the 2026 ESMO Congress. The trial is a randomized, controlled, double-blind, registrational Phase III clinical study evaluating ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for ad......
25.10.26 - 16:33
Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 2026 Presidential Symposium (PR Newswire)
 
HONG KONG, Oct. 25, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced the presentation of results from the randomized, controlled, double-blind, multicenter, registrational Phase III HARMONi-GI1 trial (AK112-309). The study evaluated first-in-class ivonescimab plus......
23.10.26 - 07:45
Research: M Stanley: Outlook for 4Q26 Catalysts in China Biotech Stocks; Sector Rated "Attractive" (AAStocks)
 
Morgan Stanley published a research report on China biotech stocks, identifying and previewing potential catalysts that may affect sector share prices in 4Q26. The sector is rated "Attractive".Regarding AKESO (09926.HK), the broker expects the progression-free survival (PFS) benefit in HARMONi-3 may weaken slightly, but treatmen......
21.10.26 - 14:45
Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer (PR Newswire)
 
Becomes the 7th International Registrational Clinical Trial for Ivonescimab Clinical Trial Site Activations in the United States Expected to Begin Q4 2026 HONG KONG, Oct. 21, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced that Summit Therapeutics Inc. (NASDAQ: SMMT), its......
20.10.26 - 07:30
Research: CICC: ZIJIN GOLD INTL , KB LAMINATES , SWIREPROPERTIES and Others Meet HSI Inclusion Criteria (AAStocks)
 
CICC published a report previewing the results of the annual review of Hang Seng Indexes, which Hang Seng Indexes Company is scheduled to announce after market close on Nov 20. The broker expects that ZIJIN GOLD INTL (02259.HK), KB LAMINATES (01888.HK), SWIREPROPERTIES (01972.HK), AKESO (09926.HK), XPENG-W (09868.HK), Z.AI (0251......
14.10.26 - 12:30
HKD1.2B Southbound Trading Net Inflow to BABA-W (AAStocks)
 
There was HKD1.2 billion, HKD772 million and HKD278.2 million Southbound Trading net inflow to BABA-W (09988.HK), AKESO (09926.HK) and MEITUAN-W (03690.HK).There was HKD784.6 million, HKD493 million and HKD487.4 million Southbound Trading net outflow from SMIC (00981.HK), YOFC (06869.HK) and XIAOMI-W (01810.HK).For Southbound Tr......
14.10.26 - 07:06
Akeso-Aktie unter Druck: Kapitalerhöhung mit deutlichem Abschlag belastet Kurs (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
14.10.26 - 03:45
AKESO Places Shares at 6.9% Discount, Raises Up to HKD1.94 billion Net (AAStocks)
 
AKESO (09926.HK) proposed to place 20 million shares at a placing price of HKD97.76 per share, representing a discount of approximately 6.9% to the closing price of HKD105 per share as quoted on the Stock Exchange on the last full trading day (13th) prior to the date of the placing agreement.The placing shares represent approxim......
14.10.26 - 03:00
AKESO Places Shares at 6.9% Discount, Raises Net Proceeds of Over HKD1.9 billion (AAStocks)
 
AKESO (09926.HK) announced a plan to place 20 million new shares at HKD97.76 per share. The placing shares represent approximately 2.13% of the enlarged issued share capital. The placing price represents a discount of approximately 6.9% to yesterday's (13th) closing price of HKD105.Assuming the placing is fully completed, gross ......
10.10.26 - 06:42
First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer (PR Newswire)
 
HONG KONG, Oct. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, as monotherapy in......
06.10.26 - 05:30
Research: CLSA: China Healthcare Licensing Deal Momentum Strengthens; Maintains Positive View on Sector (AAStocks)
 
CLSA published a research report stating that China's healthcare sector has recently completed four major business development (BD) and collaboration deals in succession. The four deals involve HENGRUI PHARMA (01276.HK) and Novo Nordisk A/S (NVO.US), AKESO (09926.HK) and AstraZeneca PLC Ordinary Shares (AZN.US), Regeneron Pharma......
02.10.26 - 12:15
Research: BofAS: Three Collaborations in China's Pharma/Biotech Sector Strengthen Sector Momentum, Raises TP for HENGRUI PHARMA and SBP GROUP (AAStocks)
 
BofAS published a research report stating that three recent collaborations in China's pharmaceutical/biotechnology sector have strengthened sector momentum. The broker raised the TP for SBP GROUP (01177.HK) from HKD7.3 to HKD7.4 and reiterated its "Buy" rating. It also maintained the "Buy" rating and HKD136 TP for AKESO (09926.H......
30.09.26 - 12:45
HKD1.4B Southbound Trading Net Inflow to TENCENT (AAStocks)
 
There was HKD1.4 billion, HKD178.8 million and HKD166.7 million Southbound Trading net inflow to TENCENT (00700.HK), WUXI BIO (02269.HK) and MINIMAX-W (00100.HK).There was HKD971.4 million, HKD145.9 million and HKD17.2 million Southbound Trading net outflow from SMIC (00981.HK), Z.AI (02513.HK) and AKESO (09926.HK).For Southboun......
30.09.26 - 06:15
Research: Citi: AstraZeneca PLC Ordinary Shares USD2 billion Investment in Summit Therapeutics Inc. Validates Ivonescimab Strength; Maintains Buy Rating on AKESO (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
30.09.26 - 06:00
Research: Daiwa: AKESO Global Partner Summit Therapeutics Inc. Secures AstraZeneca PLC Ordinary Shares Investment, Boosting Ivonescimab's Global Peak Sales Potential (AAStocks)
 
Daiwa released a research report stating that AKESO (09926.HK)'s global partner Summit Therapeutics Inc. (SMMT.US) announced on Monday evening (28 Sep, US Eastern Time) that it had signed an agreement with AstraZeneca PLC Ordinary Shares (AZN.US), under which AstraZeneca will make a strategic equity investment of USD2 billion in......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Der Geschmack hängt nicht an unseren Bedürfnissen. Der Mann muß schon sehr gesittet sein, wenn er eine Frau nach Geschmack wählen soll. - Immanuel Kant
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!